YZYBIO-B (02496) has announced that clinical results from two studies of its core national Class 1 innovative drug M701, a "CD3/EpCAM bispecific antibody," will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The studies include a Phase III registration clinical trial for malignant ascites (MA) and a Phase II clinical trial for non-small cell lung cancer (NSCLC)-related malignant pleural effusion (MPE). The marketing application for M701 was accepted by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration in May 2026, positioning it as a potential first-line standard treatment for malignant pleural and peritoneal effusions in China. Compared to the EU-approved catumaxomab, M701 demonstrates a superior safety profile and practical clinical accessibility. When compared to procedures like puncture drainage or local chemotherapy, M701 shows a higher response rate and more durable fluid control.